Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Receivables (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Receivables for 16 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 7.92% to $16.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.0 million through Dec 2025, up 7.92% year-over-year, with the annual reading at $16.0 million for FY2025, 7.92% up from the prior year.
  • Receivables for Q4 2025 was $16.0 million at Harvard Bioscience, up from $12.1 million in the prior quarter.
  • The five-year high for Receivables was $21.8 million in Q4 2021, with the low at $11.9 million in Q2 2025.
  • Average Receivables over 5 years is $16.0 million, with a median of $16.1 million recorded in 2023.
  • The sharpest move saw Receivables surged 32.14% in 2021, then dropped 26.13% in 2024.
  • Over 5 years, Receivables stood at $21.8 million in 2021, then fell by 23.49% to $16.7 million in 2022, then dropped by 3.63% to $16.1 million in 2023, then decreased by 7.66% to $14.9 million in 2024, then grew by 7.92% to $16.0 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $16.0 million, $12.1 million, and $11.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.